Cochrane Nordic, (and associates), has forwarded a complaint to the European Medicines Agency (EMA) over maladministration at the EMA in regards to the safety of HPV vaccines.

Cochrane Nordic’s corrrespondence with the EMA is accessible on this webpage: http://nordic.cochrane.org/news/complaint-filed-european-medicines-agency-over-maladministration-related-safety-hpv-vaccines

I am alerting Cochrane Nordic and the medical journal The BMJ to matters relevant to the safety of human papillomavirus (HPV) vaccines, e.g.

• the lack of evidence supporting multiple HPV vaccine doses;
• the lack of evidence for prevention of cancer; 
• the lack of scientific knowledge about HPV vaccination, i.e. scientists such as Professor Diane Harper admit “the mechanism of immunogenicity from a scientific perspective is poorly understood”;
• the novel turbo-charged aluminium adjuvants in the VLP HPV vaccine products, which are reported to induce unnaturally high antibody titres, many fold higher than natural HPV infection;
• the potential for a continuous shift in HPV types (‘type replacement’) as a result of vaccination, and the uncertainties this brings;
• fear-mongering about the risks of HPV and misleading information; 
• political interference in the implementation of HPV vaccination, e.g. in Australia, which had a domino effect in fast-tracking HPV vaccination around the world; 
• the lack of independent and objective evaluation of HPV vaccination; and
• the lack of ‘informed consent’ before HPV vaccination.

I submitted comments on these matters on Dr Richard Lehman’s 5 December 2016 BMJ blog.  Only one of my comments was published after approval by The BMJ’s lawyer, the rest have been censored pending an investigation into HPV vaccination by The BMJ’s Associate Editor Dr Peter Doshi, as advised to me personally by Dr Fiona Godlee, Editor in Chief of The BMJ (15 Feb 2017).  For information, here is a hyperlink to the comments I submitted to The BMJ:  E Hart unpublished comments re HPV vax on Richard Lehman’s BMJ Blog

My correspondence to Cochrane Nordic and The BMJ can be accessed via the following hyperlinks, see below starting from October 2016 – this matter is ongoing:

• HPV vaccines and aluminium – Your complaints over maladministration at the EMA in relation to the safety of the HPV vaccines (12 October 2016)
• Safety of the HPV vaccines – high antibody titre after vaccination (29 November 2016)
• More re unnaturally high antibody titres after HPV vaccination (9 December 2016)
• No evidence for three doses of HPV vaccines (12 December 2016)
• Fear mongering about HPV and cervical cancer – Nordic Cochrane EMA complaint re safety of the HPV vaccines (13 December 2016)
• HPV vaccination – “there is no evidence of cancers prevented”  (22 December 2016)
• Response to Fiona Godlee, Editor-in Chief of the BMJ re HPV vaccination – Richard Lehman’s BMJ Blog item “Two is as good as three for HPV” (23 December 2016)
• Further response to Fiona Godlee, Editor-in-Chief of the BMJ re HPV vaccination – Richard Lehman’s BMJ Blog item “Two is as good as three for HPV” (9 January 2017)
• Further response to Fiona Godlee, Editor-in-Chief of the BMJ re HPV vaccination and my comments on Richard Lehman’s BMJ Blog item (23 January 2017)
• The history of questionable fast-tracked global HPV vaccination (25 January 2017)
• HPV vaccination and ethics – an email to Dr Richard Lehman re his BMJ Blog (31 January 2017)
• Reply to Fiona Godlee, Editor-in-Chief of The BMJ re HPV vaccination (31 January 2017)
• Ethics approval and consent re HPV vaccination studies – email to Fiona Godlee, Editor-in-Chief of The BMJ (9 February 2017)
• HPV vaccination and ‘informed consent’ – response to Fiona Godlee, Editor-in-Chief of The BMJ (15 February 2017)
• More re meningococcal W and B vaccination (including conflicts of interest in vaccination policy – also relevant to HPV vaccination) (25 March 2017)
• Failure to disclose conflicts of interest / HPV vaccination / Dave Hawkes / Patrick Stokes / Sue Ieraci (12 April 2017)
• Email to Fiona Godlee BMJ re HPV vaccination – Cochrane & Co – Heidi Larson Vaccine Confidence Project (22 January 2018)